Home / GORE^® TAG^® Thoracic Endoprosthesis /

Challenge: Advancing endovascular therapy to treat thoracic disease

Choice: Conformable GORE^® TAG^® Thoracic Endoprosthesis

Traditional treatment of diseases of the thoracic aorta has involved high-risk surgery resulting in long hospital stays and painful recoveries. For more than a decade, Gore has worked alongside physicians in the evolution of the GORE® TAG® Thoracic Endoprosthesis. Our collaboration has resulted in the distribution of more than 48,000 devices for the treatment of more than 28,000 patients worldwide¹.

The GORE® TAG® Device has remained the leading option for less invasive treatment of thoracic aneurysms and lesions with a proven safety record, which is supported by more than ten years of worldwide clinical data. The next generation Conformable GORE® TAG® Device was engineered for flexibility and conformability in tortuous anatomy to meet the needs of individual patients.

The device is the only durable ePTFE thoracic endoprosthesis that offers conformability and ease of use, while accommodating tapered anatomy, resisting compression and maintaining patency in small diameter thoracic aortas characteristic of young patients. The Conformable GORE® TAG® Device has an exclusive oversizing window range from 6–33%, allowing physicians to choose the appropriate radial force to create the appropriate radial fit of the device for the patient anatomy and specific etiology.

The device is available in diameters of 21–45 mm, allowing for the treatment of patients with aortic diameters of 16–42 mm. Tapered device configurations are also available. The simple, single-step deployment system provides flexibility for navigating tortuous anatomy. Paired with the GORE® DrySeal Sheath, which optimizes control with minimal blood loss, the Conformable GORE® TAG® Thoracic Endoprosthesis exemplifies Gore’s continued commitment to innovative solutions intended to maximize patient outcomes.

¹ 48,000 devices distributed worldwide divided by 1.7 devices